Skip to main content
SpringerLink
Log in

Psoriasis inversa

Inverse psoriasis

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Bei Psoriasis inversa treten chronisch entzündliche Hautveränderungen fast ausschließlich in den intertriginösen Bereichen inklusive der Rima ani auf. Kolonisierungen bzw. Superinfektionen mit Candida spp. und Bakterien sind nicht selten. Patienten haben einen hohen Leidensdruck und fühlen sich stigmatisiert, speziell hinsichtlich intimer zwischenmenschlicher Kontakte. Nach Ausschluss relevanter Differenzialdiagnosen richtet sich die Therapie nach dem klinischen Bild, nach Verlauf, Vor- und Begleiterkrankungen. Die Substanzen, die bei Psoriasis vulgaris wirksam sind, sind prinzipiell auch bei Psoriasis inversa wirksam, wobei die Anwendung im Off-label-Bereich erfolgt. Kontrollierte klinische Studien liegen lediglich für topische Ascomycine vor.

Abstract

Inverse psoriasis is clinically defined by chronic inflammatory lesions in intertrigineous areas. Colonisation or infection with Candida ssp. or bacteria is common. The disease-related quality of life is significantly reduced especially regarding sexual behavior. After the exclusion of relevant differential diagnoses, therapy should be adapted to the clinical outcome and potential comorbidities. Substances which are efficacious in psoriasis vulgaris are generally efficacious in inverse psoriasis, but have to be used off-label. Controlled clinical studies are only available for topical ascomycin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Carrascosa JM, Soria X, Domingo H et al (2007) Treatment of inverse psoriasis with excimer therapy and tacrolimus ointment. Dermatol Surg 33(3):361–363

    CAS  PubMed  Google Scholar 

  2. Farber EM, Nall L (1992) Perianal and intergluteal psoriasis. Cutis 50(5):336–338

    CAS  PubMed  Google Scholar 

  3. Gribetz C, Ling M, Lebwohl M et al (2004) Pimecrolimus cream 1 % in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 51(5):731–738

    Article  PubMed  Google Scholar 

  4. Guglielmetti A, Conlledo R, Bedoya J et al (2012) Inverse psoriasis involving genital skin folds: successful therapy with dapsone. Dermatol Ther (Heidelb) 2:15

    Article  Google Scholar 

  5. Kalb RE, Bagel J, Korman NJ et al (2009) Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 60(1):120–124

    Article  PubMed  Google Scholar 

  6. Lebwohl M, Freeman AK, Chapman MS et al (2004) Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 51(5):723–730

    Article  PubMed  Google Scholar 

  7. Lysell J, Tessma M, Nikamo P et al (2014) Clinical characterisation at onset of childhood psoriasis – a cross sectional study in Sweden. Acta Derm Venereol. doi:10.2340/00015555-1986 (Epub ahead of print)

  8. Mafong EA, Friedman PM, Kauvar AN et al (2002) Treatment of inverse psoriasis with the 308 nm excimer laser. Dermatol Surg 28(6):530–532

    PubMed  Google Scholar 

  9. Nast A, Boehncke WH, Mrowietz U et al (2011) S3-guidelines for the treatment of psoriasis vulgaris. Update 2011. J Dtsch Dermatol Ges 9(Suppl 2):S1–S104

    PubMed  Google Scholar 

  10. Phan C, Sigal ML, Estève E et al (2014) Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol. doi:10.1111/jdv.12850 (Epub ahead of print)

  11. Prinz JC (2009) The role of streptococci in psoriasis. Hautarzt 60(2):109–115

    Article  CAS  PubMed  Google Scholar 

  12. Rouzaud M, Sevrain M, Villani AP et al (2014) Is there a psoriasis skin phenotype associated with psoriatic arthritis? J Eur Acad Dermatol Venereol 28(Suppl 5):17–26 (Systematic literature review)

    Article  PubMed  Google Scholar 

  13. Saber M, Brassard D, Benohanian A (2011) Inverse psoriasis and hyperhidrosis of the axillae responding to botulinum toxin type A. Arch Dermatol 147(5):629–630

    Article  PubMed  Google Scholar 

  14. Syed ZU, Khachemoune A (2011) Inverse psoriasis: case presentation and review. Am J Clin Dermatol 12(2):143–146

    Article  PubMed  Google Scholar 

  15. Tavarela Veloso F (2004) Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther 20(Suppl 4):50–53

    Article  PubMed  Google Scholar 

  16. Wollenberg A, Bieber T (2009) Proactive therapy of atopic dermatitis – an emerging concept. Allergy 64:276–278

    Article  CAS  PubMed  Google Scholar 

  17. Zanchi M, Favot F, Bizzarini M et al (2008) Botulinum toxin type-A for the treatment of inverse psoriasis. J Eur Acad Dermatol Venereol 22:431–436

    Article  CAS  PubMed  Google Scholar 

  18. Zeichner JA (2010) Use of topical coal tar foam for the treatment of psoriasis in difficult-to-treat areas. J Clin Aesthet Dermatol 3:37–40

    PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Facharzt für Dermatologie und Venerologie, Allergologie, Dermatologikum Hamburg, Stephansplatz 5, 20354, Hamburg, Deutschland

    P. Weisenseel & K. Reich

Authors
  1. P. Weisenseel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Reich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Weisenseel.

Ethics declarations

Interessenkonflikt

K. Reich hat als Berater oder Referent oder im Rahmen von klinischen Studien von Firmen, die Arzneimittel zur Therapie der Psoriasis vulgaris/Psoriasis-Arthritis herstellen, finanzielle Zuwendungen erhalten:  Abbvie, Amgen, Biogen-Idec, Celgene, Centocor, Covagen, Forward Pharma, GSK, Janssen-Cilag, LEO Pharma, Lilly, Medac, MSD, Novartis, Pfizer, Vertex, und Takeda.

P. Weisenseel hat als Berater oder Referent oder im Rahmen von klinischen Studien von Firmen, die Arzneimittel zur Therapie der Psoriasis vulgaris/Psoriasis-Arthritis herstellen, finanzielle Zuwendungen erhalten:  Abbvie, Biogen-Idec, Dexcel, GSK, Janssen-Cilag, LEO Pharma, Medac, MSD, Novartis und Pfizer.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weisenseel, P., Reich, K. Psoriasis inversa. Hautarzt 66, 408–412 (2015). https://doi.org/10.1007/s00105-015-3628-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-015-3628-7

Schlüsselwörter

Keywords

Search

Navigation